Ching-Feng Chiu
Overview
Explore the profile of Ching-Feng Chiu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiu C, Guerrero J, Regalado R, Zhou J, Notarte K, Lu Y, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 39976390
Upon further reflection and in consultation with her academic advisors, Ms [...].
2.
Hsu T, Wang W, Chen H, Wang T, Su C, Liao P, et al.
Cancer Metab
. 2025 Feb;
13(1):7.
PMID: 39930542
Background: Lactate dehydrogenase A (LDHA) can regulate tumorigenesis and cancer progression. Nevertheless, whether the regulation of LDHA is involved in the development of gemcitabine resistance in PDAC has not yet...
3.
Chiu C, Lin H, Su Y, Chen H, Hung S, Huang S
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519347
Dicer, a cytoplasmic type III RNase, is essential for the maturation of microRNAs (miRNAs) and is implicated in cancer progression and chemoresistance. Our previous research demonstrated that phosphorylation of Dicer...
4.
Chiu C, Guerrero J, Regalado R, Zhou J, Zamora M, Notarte K, et al.
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456607
Cancer remains a global health challenge, characterized not just by uncontrolled cell proliferation but also by the complex metabolic reprogramming that underlies its development and progression. This review delves into...
5.
Trakoonsenathong R, Chiu C, Saengboonmee C
World J Gastroenterol
. 2024 Oct;
30(34):3862-3867.
PMID: 39350782
Glucagon-like peptide-1 receptor (GLP-1R) agonist, a subgroup of incretin-based anti-diabetic therapies, is an emerging medication with benefits in reducing blood glucose and weight and increasing cardiovascular protection. Contrarily, concerns have...
6.
Park J, Su Y, Fan C, Chen H, Qiu Y, Chen L, et al.
Exp Mol Med
. 2024 Sep;
56(9):2065-2081.
PMID: 39294443
Ferritin, comprising heavy (FTH1) and light (FTL) chains, is the main iron storage protein, and pancreatic cancer patients exhibit elevated serum ferritin levels. Specifically, higher ferritin levels are correlated with...
7.
Hsu T, Wang W, Chen A, Chiu C, Liao P, Chen H, et al.
J Cell Physiol
. 2024 Aug;
239(12):e31416.
PMID: 39164986
Pancreatic cancer has one of the highest fatality rates and the poorest prognosis among all cancer types worldwide. Gemcitabine is a commonly used first-line therapeutic drug for pancreatic cancer; however,...
8.
Khawkhiaw K, Chomphoo S, Kunprom W, Thithuan K, Sorin S, Yueangchantuek P, et al.
Transl Gastroenterol Hepatol
. 2024 Aug;
9:36.
PMID: 39091665
Background: Diabetes mellitus (DM) is associated with the increased risk of development and the advancement of cholangiocarcinoma (CCA). High glucose levels were previously shown for upregulating interleukin-1β (IL-1β) in CCA...
9.
Trakoonsenathong R, Kunprom W, Aphivatanasiri C, Yueangchantuek P, Pimkeeree P, Sorin S, et al.
Sci Rep
. 2024 Jun;
14(1):13726.
PMID: 38877189
Glucagon-like peptide 1 receptor (GLP-1R) agonist is an emerging anti-diabetic medication whose effects on the risk and progression of cholangiocarcinoma (CCA) are controversial. This study aimed to elucidate the roles...
10.
Yeh Y, Hsu T, Su Y, Wang C, Liao P, Chiu C, et al.
Aging (Albany NY)
. 2023 Nov;
15(22):12873-12889.
PMID: 37976135
Dacarbazine (DTIC) is the primary first-line treatment for advanced-stage metastatic melanoma; thus, DTIC resistance is poses a major challenge. Therefore, investigating the mechanism underlying DTIC resistance must be investigated. Dicer,...